Company: ELV
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0001156039-25-000057
Chunk: 71

Company: Elevance Health, Inc.
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 8
Chunk 71
---
 Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

There have been no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

For information regarding legal proceedings at March 31, 2025, see the “Litigation and Regulatory Proceedings” and “Other Contingencies” sections of Note 11, “Commitments and Contingencies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which information is incorporated herein by reference.

ITEM 1A.    RISK FACTORS

There have been no material changes to the risk factors disclosed in Part I, Item 1A of our 2024 Annual Report on Form 10-K.

-50-

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table presents information related to our repurchases of common stock for the periods indicated:

PeriodTotal Numberof SharesPurchased1 AveragePrice Paidper ShareTotal Numberof SharesPurchasedas Partof PubliclyAnnouncedPrograms2ApproximateDollar Valueof Sharesthat May YetBe PurchasedUnder thePrograms(in millions, except share and per share data)    January 1, 2025 to January 31, 20251,051,297 $387.02 1,050,101 $8,894 February 1, 2025 to February 28, 2025642,846 392.31 642,419 8,642 March 1, 2025 to March 31, 2025658,695 413.15 529,681 8,421 2,352,838 2,222,201 

1    Total number of shares purchased includes 130,637 shares delivered to or withheld by us in connection with employee payroll tax withholding upon the exercise or vesting of stock